Sava reposted this
Health monitoring startup, Sava, has developed a real-time, painless microsensor that can detect molecules in the interstitial fluid, just under the skin. The smart, wearable patch connectors directly to a user’s phone. Developed by bioengineers from Imperial College London, the company’s first microsensor will focus on glucose monitoring for people with diabetes. #healthtech #startup #innovation Renato Circi Rafaël Michali
We are very excited to share that Sava is emerging from stealth to announce that we have raised an $8 million round led by Balderton Capital and Exor Ventures! 🎉 At SAVA, we are pioneering a new standard in health monitoring. We have developed the first continuous biosensing platform offering low-cost, pain-free, and multi-biomarker sensing capabilities, powering use cases that were previously impossible outside of a lab. Traditional healthcare operates too reactively: a system marked by inefficiency, high costs and centralization. Enabling real-time access to deep health information, the very molecules flowing under our skin, will unlock a new era of preventative care. One where we can make health decisions with unprecedented knowledge of our bodies, spot issues before it's too late, and tailor our daily lives according to what uniquely works for us. We are thrilled to have the support of our investors as we work towards our goal of defining a new paradigm in health monitoring – preventative, personalized, and effortless. A special thanks to all our investors who have worked with us since day one, Sweet Capital, JamJar Investments, Exceptional Ventures, SOSV, and all our angel investors. We could not have made it this far without your support and are thrilled to continue this exciting journey with you to transform healthcare. Finally, a huge shoutout to our incredible team for their hard work. The work you do every single day, is truly breathtaking and incredibly inspiring! Thank you to Kai Nicol-Schwarz at Sifted for a great article and stay tuned for more updates as we continue to grow! 🚀 Find Sifted article here → https://lnkd.in/dgrCJUEx Read our full press release → https://lnkd.in/de4hK8pQ Check out our new website! → https://www.sava.health/ #health #healthtech #biotech #startup #diabetes #funding #CGM #investment #diabetestech #wearables #biosensor
Thanks Exceptional Ventures! It has been great working with you since the very beginning as one of our early supporters. Special thanks to Paolo Pio for all your help! Read the article here → https://lnkd.in/ecqcMfzX
Congratulations to our portfolio company, Sava, for coming out of stealth! 👏🏼⭐️ Founded by brilliant Imperial College London biomedical engineering grads, Renato Circi and Rafaël Michali, Sava has been part of our family since December 2022. They’re revolutionising HealthTech with an innovative biosensing device that uses microneedle technology to measure biomarkers from the interstitial fluid beneath the skin. Starting with glucose monitoring, they plan to expand to lactate, ketones, urea, creatinine, alcohol, and more! Their first product, a next-gen Continuous Glucose Monitor, is less invasive and dramatically more affordable than anything on the market. Sava's vision goes beyond diabetes management - they aim to transform how we understand our bodies, paving the way for precision nutrition and preventative medicine. Imagine real-time insights into your body's response to food and overall health, like having a personal lab on your arm 💪🏼. Early detection and immediate action will become the norm, keeping us healthier for longer. Paolo Pio met Ren and Raf in 2019 and was captivated by their talent and the revolutionary potential of their project. We're thrilled to partner with such visionary founders and can't wait to see your impact! 🙏 We're also excited to be investing alongside Exor Ventures and Balderton Capital. Full Tech.eu announcement here: https://lnkd.in/ecqcMfzX #ExceptionalVentures #HealthTech #Wellness #VC #CGM
Last week, Sava attended #ADA2024 in Orlando for the first time. It was great to connect with healthcare professionals, researchers, and innovators in the diabetes community. 💡 Here are our key takeaways: ⚡ Excitement about multi-analyte - Although glucose monitoring changed the diabetes space, there is increasing excitement about what multi-analyte could do for both diabetes and other health conditions. 📈 CGMs expanding to broader populations - The research presented at ADA showed a clear trend towards expanding CGM technology to more people, including those with Type 2, gestational diabetes, and pre-diabetes. To enable greater access, we need a low-cost, user-friendly, seamless solution. 🥊 The duopoly is strong, but appetite for innovation is growing - All the discussions we had reached the same conclusion: we desperately need more innovation and disruption in the diabetes space. While the CGM duopoly is stronger than ever, new players are needed to bring costs down and offer far-reaching solutions. Katy Brown and Violeta Perea Rubio were at the conference. Did we miss you? We'd love to connect! Please reach out to us to learn more about Sava and our vision for the future of preventative, personalized healthcare. Add us on LinkedIn or visit our website for more information: https://www.sava.health/ #ADA2024 #DiabetesTech #CGM #Healthtech #Sava
Thank you WellToDo for a great article! Read the full article here → https://lnkd.in/e-T-5Mb4 Read our full press release → https://lnkd.in/de4hK8pQ Check out our new website! → https://www.sava.health/
SAVA emerged from stealth with new capital, bringing its funding total to $13M. Initially positioned as a CGM, the company plans to expand beyond glucose tracking to measure lactate, sodium, ketones, alcohol, cortisol and urea levels. Sava claims its unique multi-molecule biosensors are shorter and cheaper than rivals, unlocking clinical and DTC uses – ranging from chronic illness detection to drug adherence to sports performance.
Grazie StartupItalia!! Read the full interview here → https://lnkd.in/dY85urQC Read our full press release → https://lnkd.in/de4hK8pQ Check out our new website! → https://www.sava.health/
«Tutto il sistema medico è stato costruito in modo reattivo: la persona non monitora nulla, fa un test all’anno se va bene. Di fronte ai sintomi si fanno le analisi e infine ci si cura. È un processo che a nostro avviso va fatto al contrario». Per la rubrica "Italiani dell'altro mondo", abbiamo intervistato Renato Circi, co-Ceo e co-founder di Sava. La startup biotech, con sede a Londra, ha sviluppato un cerotto dotato di micro sensori per misurare la glicemia. «In futuro affronteremo anche altre malattie». L'intervista di Alessandro Di Stefano: https://lnkd.in/dY85urQC #startup #biotech #innovazione
Thank you to Balderton Capital and James Wise for a great interview with our co-founder Renato Circi for the What's Next podcast. Learn about Ren & Rafaël Michali's journey from Imperial College to entrepreneurship, the key challenges of leading a start-up, and Sava's role in transforming healthcare. 💡 Discover how Sava is building its next-gen, multi-molecule wearable biosensor to provide health insights in real-time. Sava's technology aims to revolutionize healthcare by enabling a preventative, personalized, and painless future of health monitoring. 🎧 Tune in on Spotify, Youtube or Apple Podcasts to listen to the whole episode and dive deeper into our technology! Spotify → https://lnkd.in/e5N5kqiC Apple → https://lnkd.in/ev9V4KZb YouTube → https://lnkd.in/eY-i_h2U #Sava #health #healthtech #startup #founder #biosensor #healthmonitoring
What does the future of health monitoring look like? James Wise sat down with Sava's Renato Circi to discuss how their device will monitor molecules just under the skin, starting with glucose: Understanding what fuels our bodies is the first step to tackle preventable illnesses. Tune in here to learn more: https://lnkd.in/eY-i_h2U
